Increased platelet reactivity to the aggregatory effect of platelet activating factor, in vitro, in patients with heterozygous familial hypercholesterolaemia

Platelets

Volumn 10, Issue 2-3, 1999, Pages 124-131

  Elisaf, M ^a   Karabina, S A P ^a   Bairaktari, E ^a   Goudevenos, J A ^a   Siamopoulos, K C ^a   Tselepis, Alexandros D ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THROMBOCYTE ACTIVATING FACTOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; CORONARY RISK; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE ACTIVATION;

EID: 0032938882     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537109909169174     Document Type: Article

References (49)

1. 1. Goldstein JL, Brown MS. Familial hypercholesterolemia. In: Scriver, CR, Beaudet AL, Sly WS, Vall D, eds. The Metabolic Basis of Inherited Disease, 6th edn. McGraw-Hill, New York, NY, 1989: 1215-50.
2. 2. Scientific Steering Committee. Risk of fatal heart disease in familial hypercholesterolemia. Br Med J 1991; 303: 893-6.
3. 3. Hill JS, Hayden MR, Frohlich J, Pritchard PII. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler Thromb 1991; 11: 290-7.
4. 4. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823-8.
5. 5. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA 1986; 256: 2835-8.
6. 6. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes, part 2. N Engl J Med 1992; 326: 242-50.
7. 7. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes, part 2. N Engl J Med 1992; 326: 310-8.
8. 8. Carvalho ACA, Colman RW, Lees RS. Platelet function in hyperlipoproteinemia. N Engl J Med 1974; 290: 434-8.
9. 9. Willerson JT, Golino P, Eidt J, Campbell WB, Buja M. Specific-platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation 1989; 80: 198-205.
10. 10. Davi G, Avema M, Catalano I, Barbagallo C, Ganci A, Notarbartolo A, Ciabattoni G, Partono C. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation 1992; 85: 1792-8.
11. 2 by platelets in vitro. N Engl J Med 1980; 302: 6-10.
12. 2 formation in type II hyperlipoproteinaemic patients. Eur J Clin Invest 1984; 14: 329-33.
13. 13. Betteridge DJ, Cooper MB, Saggerson ED, Prichard BNC, Tan KCB, Ling E, Barbera G, McCarthy S, Smith CCT. Platelet function in patients with hypercholesterolaemia. Eur J Clin Invest 1994; 24 (suppl. 1): 30-3.
14. 14. Coumar A, Gill JK, Barradas MA, O'Donoghue S, Jeremy JY, Mikhailidis DP. The effect of treatment with simvastatin on platelet function indices in hypercholesterolaemia. J Drug Dev 1991; 4: 79-86.
15. 15. Zimmerman GA, Prescott SM, McIntyre TM. Platelet-activating factor. A fluid-phase and cell-associated mediator of inflammation. In: Gallin, JI, Goldstein, IM, Snyderman, R, eds. Inflammation, Basic Principles and Clinical Correlates. New York: Raven Press, 1993: 149-75.
16. 16. Marcus AJ, Safier LB, Ullman HL, Wong KTH, Broekman MJ, Weksler BB, Kaplan KL. Effects of acetyl glyceryl ether phosphorylcholine on human platelet function in vitro. Blood 1981; 58: 1027-31.
17. 17. Braquet, P., Godfroid, J. Conformation properties of the PAF-acether receptor on platelets based on structure-activity studies. In: Synder F., ed. Platelet-activating Factor and Related Lipid Mediators. New York: Plenum Press, 1987: 153-90.
18. 18. Lepran J, Lefer AM. Ischemia aggravating effects of platelet-activating factor in acute myocardial ischemia. Basic Res Cardiol 1985; 80: 135-41.
19. 19. Zimmerman GA, McIntyre TM, Prescott SM. Perspectives series: cell adhesion in vascular biology. Adhesion and signaling in vascular cell-cell interactions. J Clin Invest 1996; 98: 1699-702.
20. 20. Schwinger RHG, Bohm M, La Rosce K, Erdmann E. Existence of PAF receptors in human platelets and human lung tissue but not in the human myocardium. Am Heart J 1992; 124: 320-30.
21. 21. Siminiak T, Flores NA, Sheridan DJ. Neutrophil interactions with endothelium and platelets: possible role in the development of cardiovascular injury. Eur Heart J 1995; 16: 160-70.
22. 22. Tselepis AD, Pinckard RN. PAF-acetylhydrolase: a novel enzyme with biochemical and clinical interest. Clin Chem Enzym Comms 1992; 4: 279-90.
23. 23. Stafforini DM, Prescott SM, Zimmermann GA, McIntyre TM. Platelet-activating factor acetylhydrolase in human tissues and blood cells. Lipids 1991; 26; 979-85.
24. 24. Stafforini DM, McIntyre TM, Carter ME, Prescott SM. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem 1987; 262: 4215-22.
25. 25. Tselepis AD, Dentan C, Karabina S-AP, Chapman MJ, Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol 1995; 15: 1764-73.
26. 26. Stremler KE, Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase: oxidatively fragmented phospholipids as substrates. J Biol Chem 1991; 266: 11095-103.
27. 27. Smiley PL, Stremler KE, Prescott SM, Zimmerman GA, McIntyre TM. Oxidatively fragmented phosphatidylcholines activate human neutrophils through the receptor for platelet-activating factor. J Biol Chem 1991; 266: 11104-110.
28. 28. Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM, Prescott SM. Oxidatively modified LDL contains phospholipids with platelet activating factor-like activity and stimulates the growth of smooth muscle cells. J Clin Invest 1995; 96: 2322-30.
29. 29. Karabina S-AP, Liapikos ThA, Grekas G, Goudevenos J, Tselepis AD. Distribution of PAF-acetylhydrolase activity in human plasma low density lipoprotein subfractions. Biochim Biophfs Acta 1994; 1213: 34-8.
30. 30. Karabina S-AP, Elisaf M, Bairaktari E, Tzallas C, Siamopoulos KC, Tselepis AD. Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia. Eur J Clin Invest 1997; 27: 595-602.
31. 31. Tselepis AD, Tsoukatos D, Droudes C, Donas A, Evangelou A. Platelet response to the aggregatory effect of platelet activating factor (PAF) ex vivo in patients with acute myocardial infarction. Eur J Clin Invest 1991; 21: 490-6.
32. 32. Goudevenos J, Tselepis AD, Tsoukatos D, Grekas G, Kritikakos J, Sideris D. Platelet aggregability to platelet activating factor at rest and after exercise in patients with coronary artery disease. Eur Heart J 1995; 16: 1036-43.
33. 33. Williams RR, Schumacher MC, Barlow GK, Hunt SC, Ware JL, Pratt M, Latham BD. Documented need for more effective diagnosis and treatment of familial hypercholesterolemia according to data from 502 heterozygotes in Utah. Am J Cardiol 1993; 72: 18D-24D.
34. 34. Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, Hopkins PN. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993; 72: 171-6.
35. 35. Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172-7.
36. 36. Hochgraf E, Levy Y, Aviram M, Brook JG, Cogan U. Lovastatin decreases plasma and platelet cholesterol levels and normalizes elevated platelet fluidity and aggregation in hypercholesterolemic patients. Metabolism 1994; 43: 11-7.
37. 37. Surya II, Akkerman J-WN. The influence of lipoproteins on blood platelets. Am Heart J 1993; 125: 272-5.
38. 38. Aviram M. Platelets and the arterial wall lesion. Curr Opin Lipidol 1992; 3: 344-8.
39. 39. Aviram M. Effect of lipoproteins and platelets on macrophage cholesterol metabolism. In: Harris JR, ed. Blond Cell Biochem. New York: Plenum Publishing, 1992; 2: 179-207.
40. 40. Heptinstall S, Mulley GP, Taylor PM, Mitchell JRA. Platelet-release reaction in myocardial infarction. Br Med J 1980; 280: 80-1.
41. 41. Mikhailidis DP, Barradas MA, Mier A, Boag F, Jeremy JY, Havard CWH, Dandona P. Platelet function in patients admitted with a diagnosis of myocardial infarction. Angiology 1987; 38: 36-44.
42. 42. Witzum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785-92.
43. 43. Liapikos ThA, Antonopoulou S, Karabina S-AP, Tsoukatos DC, Demopoulos CA, Tselepis AD. Platelet-activating factor formation during oxidative modification of low density lipoprotein when PAF-acetylhydrolase has been inactivated. Biochim Biophys Acta 1994; 1212: 353-60.
44. 44. Ardlie NG, Selley ML, Simons LA. Platelet activation by oxidatively modified low density lipoproteins. Atherosclerosis 1989; 76: 117-24.
45. 45. Siminiak T, Flores NA, Sheridan DJ. Neutrophil interactions with endothelium and platelets: possible role in the development of cardiovascular injury. Eur Heart J 1995; 16: 160-70.
46. 46. Prescott SM, Zimmerman GA, McIntyre TM. Human endothelial cells in culture produce platelet-activating factor (1-alky1-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin. Proc Natl Acad Sci USA 1984; 81: 3534-8.
47. 47. Zimmerman GA, McIntyre TM, Mehra M, Prescott SM. Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion. J Cell Biol 1990; 110: 529-40.
48. 48. Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM. The platelet activating factor acetylhydrolase from human plasma prevents oxidative modification of low density lipoprotein. Trans Am Assoc Physiol 1993; 106: 44-63.
49. 49. Stafforini DM, Carter ME, Zimmerman GA, McIntyre TM, Prescott SM. Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma. Proc Natl Acad Sci USA 1989; 86: 2393-7.